Exelixis | EXEL - 净收入



金融业
股票价格
USD
资产
USD 2.49B
现金及等价物
USD 281.45M
销售成本
USD 20.66M
流动资产
USD 1.25B
流动负债
USD 361.93M
债务
USD 165.93M
EBIT
USD 248.41M
EBITDA
USD 255.4M
员工
1.15K
EPS每股收益
USD 0.91
股本和储备
USD 1.84B
销售毛利
USD 608.03M
债务利息支出
USD 23.4M
利息收入
USD 14.21M
市值
USD 14.53B
净收入
USD 212.05M
营业费用
USD 380.28M
营业利润
USD 248.41M
普通股股本
USD 248.89M
PE价格收益
18.02
税前利润
USD 262.68M
销售收入
USD 628.69M
销售和管理费用
USD 147.63M
股票
USD 28.73M
贸易债权人
USD 39.06M
应收帐款人
USD 322.21M


净收入 更改 日
Acadia Pharmaceuticals USD 31.5M 27.86M 2026-06
Agios Pharmaceuticals USD -99.11M 8.93M 2026-03
Akebia Therapeutics USD -12.24M 12.78M 2025-12
Amgen USD 2.38B 556M 2026-06
AstraZeneca USD 2.51B 573M 2026-06
Bayer EUR 219M 2.54B 2026-06
BioMarin Pharmaceutical USD 44.76M 60.76M 2026-06
Bristol-Myers Squibb USD 3.32B 640M 2026-06
Cytokinetics USD -198.76M 7.27M 2026-06
Eisai JPY 18.24B 21.49B 2026-06
Eli Lilly USD 7.1B 301M 2026-06
Exelixis USD 212.05M 1.58M 2026-06
Genmab DKK 303M 250M 2026-06
Glaxosmithkline GBP 1.74B 890.94M 2026-03
Incyte USD 585.6M 282.27M 2026-06
Ionis Pharmaceuticals USD -114.65M 21.65M 2026-06
MacroGenics USD -36.77M 22.62M 2026-03
Merck USD -1.34B 2.9B 2026-06
Moderna USD -1.34B 517M 2026-03
Nektar Therapeutics USD -44.9M 8.82M 2026-03
Neurocrine Biosciences USD 144.4M 53.5M 2026-06
Novartis USD 3.26B 108M 2026-06
Pfizer USD -248M 2.94B 2026-06
Puma Biotechnology USD 20.32M 24.85M 2024-09
Sanofi EUR 1.61B 2.42B 2026-03
Takeda JPY 113.2B 137.52B 2026-06
Ultragenyx Pharmaceutical USD -185M 56M 2026-03
Xencor USD -21.73M 107.19M 2026-06